TG 100801
Alternative Names: TG 100572; TG100801Latest Information Update: 04 Mar 2011
At a glance
- Originator TargeGen
- Class Anti-inflammatories; Benzazepines; Benzoates; Eye disorder therapies; Pyrrolidines; Small molecules
- Mechanism of Action Src-family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy; Eye disorders
Most Recent Events
- 04 Mar 2011 No development reported - Phase-I for Eye disorders in USA (Ophthalmic)
- 04 Mar 2011 No development reported - Phase-II for Age-related macular degeneration in USA (Ophthalmic)
- 04 Mar 2011 No development reported - Preclinical for Diabetic macular oedema in USA (Ophthalmic)